Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab

Pigment Cell and Melanoma Research

Volumn 28, Issue 5, 2015, Pages 611-612

  Minor, David R ^a   Puzanov, Igor ^b   Callahan, Margaret K ^c   Hug, Bruce A ^d   Hoos, Axel ^d  

^a California Pacific Center for Melanoma Research and Treatment   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DABRAFENIB; IPILIMUMAB; METHYLPREDNISOLONE; PREDNISONE; TRAMETINIB; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; OXIME; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COLITIS; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTESTINE PERFORATION; LETTER; METASTATIC MELANOMA; MIDDLE AGED; PANCOLITIS; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); COLON; COMPLICATION; DRUG EFFECTS; IMMUNOTHERAPY; MELANOMA; PROCEDURES; SKIN NEOPLASMS;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COLITIS; COLON; FEMALE; HUMANS; IMIDAZOLES; IMMUNOTHERAPY; MELANOMA; MIDDLE AGED; OXIMES; PYRIDONES; PYRIMIDINONES; SKIN NEOPLASMS;

EID: 84939258997     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12383     Document Type: Letter

References (10)

1. Callahan, M.K., Masters, G., Pratilas, C.A. et al. (2014). Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol. Res. 2, 70-79.
2. Flaherty, K.T., Infante, J.R., Daud, A. et al. (2012a). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703.
3. Flaherty, K.T., Robert, C., Hersey, P. et al. (2012b). Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107-114.
4. Hodi, F.S., O'Day, S.J., McDermott, D.F. et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
5. Hu-Lieskovan, S., Robert, L., Moreno, B.H. et al. (2014). Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J. Clin. Oncol. 32, 2248-2254.
6. Ipilimumab package insert (2014). (Accessed August 26, 20124 at http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125377s055lbl.pdf).
7. Kinugasa, T., Sakaguchi, T., Gu, X. et al. (2000). Claudins regulate the intestinal barrier in response to immune mediators. Gastroenterology 118, 1001-1011.
8. Long, G.V., Stroyakovskiy, D., Gogas, H. et al. (2014). Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371, 1877-1888.
9. Robert, C., Kaaraszewska, B., Schachter, J. et al. (2015). Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30-39.
10. Sumimoto, H., Imabayashi, F., Iwata, T. et al. (2006). The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203, 1651-1656.